aTyr Pharma (ATYR)
(Delayed Data from NSDQ)
$1.72 USD
-0.04 (-2.27%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $1.73 +0.01 (0.58%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Income Statements
Fiscal Year end for aTyr Pharma, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 10 | 0 | 10 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 10 | 0 | 10 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 55 | 57 | 34 | 26 | 23 |
Income After Depreciation & Amortization | -55 | -46 | -34 | -16 | -23 |
Non-Operating Income | 5 | 1 | 0 | 0 | -1 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -50 | -45 | -34 | -16 | -24 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -50 | -45 | -34 | -16 | -24 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -50 | -45 | -34 | -16 | -24 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -55 | -44 | -32 | -14 | -21 |
Depreciation & Amortization (Cash Flow) | 0 | 2 | 2 | 2 | 2 |
Income After Depreciation & Amortization | -55 | -46 | -34 | -16 | -23 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 53.61 | 28.42 | 19.08 | 9.16 | 3.36 |
Diluted EPS Before Non-Recurring Items | -0.94 | -1.60 | -1.77 | -1.77 | -7.03 |
Diluted Net EPS (GAAP) | -0.94 | -1.60 | -1.77 | -1.77 | -7.03 |
Fiscal Year end for aTyr Pharma, Inc falls in the month of December .
All items in Millions except EPS data.
9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.24 | 0.00 | 0.35 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.24 | 0.00 | 0.35 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 17.31 | 16.87 | 15.96 | 12.97 | 13.56 |
Income After SG&A, R&D, and Dept/Amort Expenses | -17.31 | -16.63 | -15.96 | -12.62 | -13.56 |
Non-Operating Income | 1.01 | 1.15 | 1.20 | 1.27 | 1.22 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -16.31 | -15.49 | -14.76 | -11.34 | -12.34 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | -0.02 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -16.31 | -15.49 | -14.76 | -11.34 | -12.34 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -16.31 | -15.49 | -14.75 | -11.34 | -12.35 |
Earnings Per Share Data | 9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 |
---|---|---|---|---|---|
Average Shares | 72.28 | 66.08 | 59.26 | 57.89 | 55.14 |
Diluted EPS Before Non-Recurring Items | -0.23 | -0.23 | -0.25 | -0.20 | -0.22 |
Diluted Net EPS (GAAP) | -0.23 | -0.23 | -0.23 | -0.20 | -0.22 |